The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder.
In a randomized prospective clinical trial with an observation period of 2.5 years, a subgroup analysis was carried out for the 114 patients with bipolar I disorder (DSM-IV) regarding the prophylactic efficacy of lithium and carbamazepine. Treatment outcome was evaluated taking rehospitalization, recurrence, subclinical recurrence, concomitant medication and severe adverse effects into consideration. Special interest was paid to the enzyme-inducing properties of carbamazepine, which might lessen the efficacy of psychotropic comedication. Lithium was superior to carbamazepine in bipolar I patients for various outcome criteria. Analyses in patients without psychotropic comedication indicate that the superiority of lithium is not the result of carbamazepine reducing plasma levels of concomitant drugs.
Greil
W
W
Psychiatric Hospital, University of Munich, Germany. wgreil@psy.med.uni-muenchen.de
Kleindienst
N
N
D000328:Adult; D018692:Antimanic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy*; D002220:Carbamazepine / Q000494:pharmacology / Q000627:therapeutic use*; D004347:Drug Interactions; D004790:Enzyme Induction; D005260:Female; D006801:Humans; D016651:Lithium Carbonate / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D011446:Prospective Studies; D011619:Psychotropic Drugs / Q000493:pharmacokinetics / Q000494:pharmacology; D012008:Recurrence; D016896:Treatment Outcome
D018692:Antimanic Agents; D011619:Psychotropic Drugs; D016651:Lithium Carbonate; D002220:Carbamazepine